The Manufacturers Life Insurance Company Acquires 2,729 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

The Manufacturers Life Insurance Company raised its holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 14.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,734 shares of the biotechnology company’s stock after purchasing an additional 2,729 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Aldeyra Therapeutics were worth $72,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD boosted its holdings in shares of Aldeyra Therapeutics by 7.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 48,273 shares of the biotechnology company’s stock worth $158,000 after buying an additional 3,446 shares during the last quarter. Providence Wealth Advisors LLC grew its position in shares of Aldeyra Therapeutics by 16.3% during the 2nd quarter. Providence Wealth Advisors LLC now owns 25,000 shares of the biotechnology company’s stock valued at $84,000 after acquiring an additional 3,500 shares during the period. Laidlaw Wealth Management LLC increased its stake in shares of Aldeyra Therapeutics by 32.6% during the 2nd quarter. Laidlaw Wealth Management LLC now owns 16,875 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 4,150 shares during the last quarter. BNP Paribas Financial Markets increased its stake in shares of Aldeyra Therapeutics by 23.4% during the 1st quarter. BNP Paribas Financial Markets now owns 25,278 shares of the biotechnology company’s stock worth $83,000 after purchasing an additional 4,797 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. raised its holdings in shares of Aldeyra Therapeutics by 8.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 88,122 shares of the biotechnology company’s stock worth $292,000 after purchasing an additional 6,944 shares during the period. 59.71% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Aldeyra Therapeutics in a report on Friday, August 9th.

Aldeyra Therapeutics Stock Up 2.7 %

NASDAQ ALDX opened at $5.70 on Monday. The company has a market cap of $338.66 million, a PE ratio of -11.18 and a beta of 1.44. Aldeyra Therapeutics, Inc has a 52 week low of $1.46 and a 52 week high of $6.55. The firm’s 50-day simple moving average is $5.53 and its two-hundred day simple moving average is $4.45.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.